Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Connect Biopharma Presents Abstract About Results From Rademikibart Global Phase 2b Trial In Patients With Moderate-to-severe Asthma At ATS 2024 international Conference

Author: Benzinga Newsdesk | May 22, 2024 04:14pm
  • Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24

     
  • Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24
    • End of Phase 2 (EoP2) meeting is scheduled with the U.S. Food and Drug Administration (FDA) for Q2 2024

Posted In: CNTB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)
CORE Finalist